Opendata, web and dolomites

MAINTRAC-Auto

MAINTRAC-Auto: Automatization and validation of a liquid biopsy assay “Maintrac-AUTO CTC-analyser” for predictive real time monitoring and success control of solid tumor cancer therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MAINTRAC-Auto project word cloud

Explore the words cloud of the MAINTRAC-Auto project. It provides you a very rough idea of what is the project "MAINTRAC-Auto" about.

relevance    individual    market    arise    patients    circulating    maintrac    diagnose    launch    acceptance    effectiveness    model    obvious    analyser    clinical    death    appropriate    primary    savings    efficiency    innovation    auto    diseases    2020    therapy    track    therapies    specialists    relapse    health    cells    adequately    sales    ctcs    us    precision    offers    assay    breast    big    drastically    business    ineffective    clinically    public    symptoms    approved    families    care    substantially    commercially    upscaling    validation    penetration    diagnostics    disease    equivalence    economic    worldwide    tumor    assays    causes    suffering    reimbursement    meanwhile    automatic    innovative    regulatory    treatment    maintenance    cancer    implications    patient    reducing    direct    prognosis    series    oncology    manual    revenue    progression    automated    monitoring    biomarker    12bn    readiness    initial    ctc    course    meet    indicator    estimate    demand    forecasts    standardized    individualize   

Project "MAINTRAC-Auto" data sheet

The following table provides information about the project.

Coordinator
SIMFO SPEZIELLE IMMUNOLOGIE FORSCHUNG UND ENTWICKLUNG GMBH 

Organization address
address: KURPROMENADE 2
city: BAYREUTH
postcode: 95448
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.simfo.de
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-03-01   to  2016-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SIMFO SPEZIELLE IMMUNOLOGIE FORSCHUNG UND ENTWICKLUNG GMBH DE (BAYREUTH) coordinator 50˙000.00

Map

 Project objective

Worldwide cancer is one of the leading causes of death and the need for more effective therapies is crucial. New precision diagnostics can identify and characterize the disease to individualize the therapy throughout the course of cancer, like our clinically approved Maintrac-CTC assay. Maintrac-CTC can track circulating tumor cells (CTCs) even in primary cancer patients to estimate prognosis and diagnose relapse well before clinical symptoms arise. Meanwhile a fully automated Maintrac AUTO analyser was established and offers a standardized state-of-art biomarker system for direct and better monitoring of disease progression and effectiveness i.e. of the maintenance therapy in breast cancer. We aim to drastically increase both effectiveness (selection of treatment most adequately for individual cancer type and phase) and efficiency (early indicator for the response level to an initial therapy) to avoid ineffective therapies, savings cost for the health care system and substantially reducing patient suffering. The objectives of the innovation project are to achieve series-production readiness and launch the system commercially with the best business model. We aim for acceptance of Maintrac CTC assays by oncology specialists through clinical validation and to achieve reimbursement by public authorities for upscaling and market penetration. In phase 1 we will show equivalence of the automatic system to the established manual method and meet regulatory requirements. In addition business opportunities and appropriate sales model will be evaluated. Forecasts for overall CTC biomarker market estimate a big market with a high demand for innovative products with expected revenue potential of US$ 12bn in 2020. Due to the obvious relevance of cancer diseases for patients, their families as well as economic implications, Maintrac will have an important impact on future cancer disease management.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAINTRAC-AUTO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MAINTRAC-AUTO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More  

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More